No auxiliary, no byproduct strategy for water-soluble prodrugs of taxoids: Scope and limitation of O-N intramolecular acyl and acyloxy migration reactions

Journal of Medicinal Chemistry

Volumn 48, Issue 7, 2005, Pages 2655-2666

  Skwarczynski, Mariusz ^a   Sohma, Youhei ^a   Noguchi, Mayo ^a   Kimura, Maiko ^a   Hayashi, Yoshio ^a   Hamada, Yoshio ^a   Kimura, Tooru ^a   Kiso, Yoshiaki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREMOPHOR; DOCETAXEL; ORGANIC SOLVENT; PACLITAXEL; PRODRUG; TAXOID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CHEMICAL REACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; MOLECULAR INTERACTION; MULTIDRUG RESISTANCE; NONHUMAN; REACTION ANALYSIS; SOLUBILITY;

ANTINEOPLASTIC AGENTS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; PRODRUGS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS; WATER;

EID: 17144381272     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049344g     Document Type: Article

References (60)

1. Wani, M. C.; Taylor, H. L.; Wall, M. E.; Coggon, P.; McPhail, A. T. Plant antitumor agents. VI. Isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 1971, 93, 2325-2327.
2. Gueritte-Voegelein, F.; Guenard, D.; Lavelle, F.; Le Goff, M. T.; Mangatal, L.; Potier, P. Relationships between the structure of taxol analogs and their antimitotic activity. J. Med. Chem. 1991, 34, 992-998.
3. Mekhail, T. M.; Markman, M. Paclitaxel in cancer therapy. Expert Opin. Pharmacother. 2002, 3, 755-766.
4. Ferlini, C.; Ojima, I.; Distefano, M.; Gallo, D.; Riva, A.; Morazzoni, P.; Bombardelli, E.; Mancuso, S.; Scambia, G. Second generation taxanes: From the natural framework to the challenge of drug resistance. Curr. Med. Chem. Anti-Cancer Agents 2003, 3, 133-138.
5. Nabholtz, J.-M.; Vannetzel, J.-M.; Llory, J.-F.; Bouffette, P. Advances in the use of taxanes in the adjuvant therapy of breast cancer. Clin. Breast Cancer 2003, 4, 187-192.
6. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations. Int. J. Pharmaceutics 2002, 235, 179-192.
7. Ng, S. S. W.; Figg, W. D.; Sparreboom A. Taxane-mediated antiangiogenesis in vitro: Influence of formulation vehicles and binding proteins. Cancer Res. 2004, 64, 821-824.
8. Ter Haar, E. Taxanes and other microtubule stabilizing agents. Exp. Opin. Ther. Patents 1998, 8, 571-586.
9. Lin, S.; Ojima, I. Recent strategies in the development of taxane anticancer drugs. Exp. Opin. Ther. Patents 2000, 10, 869-889.
10. Dubois, J.; Guenard, D.; Gueritte, F. Recent developments in antitumour taxoids. Exp. Opin. Ther. Patents 2003, 13, 1809-1823.
11. Cassinelli, G.; Lanzi, C.; Supino, R.; Pratesi, G. Zuco, V.; Laccabue, D.; Cuccuru, G.; Bombardelli, E.; Zunino, F. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer. Clin. Cancer Res. 2002, 8, 2647-2654.
12. Shionoya, M.; Jimbo, T.; Kitagawa, M.; Soga, T.; Tohgo, A. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003, 94, 459-466.
13. Sun, W.; Stevenson, J. P.; Gallagher, M. L.; Vaughn, D.; Hahn, S. M.; Haller, D. G.; Cohen, M.; Kopit, J.; Gallant, G.; O'Dwyer, P. J. Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin. Cancer Res. 2003, 9, 5221-5227.
14. Advani, R.; Fisher, G. A.; Lum, B. L.; Jambalos, C.; Cho, C. D.; Cohen, M.; Gollerkeri, A.; Sikic, B. I. Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin. Cancer Res. 2003, 9, 5187-5194.
15. Ojima, I.; Geney, R. 109881 (Aventis). Curr. Opin. Investig. Drugs 2003, 4, 737-740.
16. Nicolau, K. C.; Riemer, C.; Kerr, M. A.; Rideout, D.; Wrasidlo, W. Design, synthesis and biological activity of protaxols. Nature 1993, 364, 464-466.
17. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: Water soluble Taxol 2′-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness. J. Med. Chem. 1996, 39, 424-31.
18. Khmelnitsky, Y. L.; Budde, C.; Arnold, M. J.; Usyatinsky, A.; Clark, D. S.; Dordick, J. S. Synthesis of water-soluble paclitaxel derivatives by enzymatic acylation. J. Am. Chem. Soc. 1997, 119, 11554-11555.
19. de Groot, F. M. H.; van Berkom, L. W. A.; Scheeren, H. W. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel. Selective activation by the tumor-associated protease plasmin. J. Med. Chem. 2000, 43, 3093-3102.
20. Seligson, A. L.; Terry, R. C.; Bressi, J. C.; Douglass III, J. G.; Sovak, M. A new prodrug of paclitaxel: Synthesis of Protaxel. Anti-cancer Drugs 2001, 12, 305-313.
21. Niethammer, A.; Gaedicke, G.; Lode, H. N.; Wrasidlo, W. Synthesis and preclinical characterization of a paclitaxel prodrug with improved antitumoractivity and water solubility. Bioconjugate Chem. 2001, 12, 414-420.
22. Wrasidlo, W.; Gaedicke, G.; Guy, R. K. Renaud, J.; Pitsinos, E.; Nicolaou, K. C.; Reisfeld, R. A.; Lode, H. N. A Novel 2′-(N- methylpyridinium acetate) prodrug of paclitaxel induces superior antitumor responses in preclinical cancer models. Bioconjugate Chem. 2002, 13, 1093-1099.
23. Kirschberg, T. A.; VanDeusen, C. L.; Rothbard, J. B.; Yang, M. I; Wender, P. A. Arginine-based molecular transporters: The synthesis and chemical evaluation of releasable taxol-transporter conjugates. Org. Lett. 2003, 5, 3459-3462.
24. Rodrigues, P. C. A.; Scheuermann, K.; Stockmar, C.; Maier, G.; Fiebig, H. H.; Unger, C.; Muelhaupt, R. Kratz, F. Synthesis and in vitro efficacy of acid-sensitive poly(ethylene glycol) paclitaxel conjugates. Bioorg. Med. Chem. 2003, 13, 355-360.
25. de Groot, F. M. H.; Albrecht, C.; Koekkoek, R.; Beusker, P. H.; Scheeren, H. W. "Cascade-release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. Angew. Chem., Int. Ed. Engl. 2003, 42, 4490-4494.
26. Liu, C.; Strobl, J. S.; Bane, S.; Schilling, J. K.; McCracken, M.; Chatterjee, S. K.; Rahim-Bata, R.; Kingston, D. G. I. Design, synthesis, and bioactivities of steroid-linked Taxol analogues as potential targeted drugs for prostate and breast cancer. J. Nat. Prod. 2004, 67, 152-159.
27. Meerum Terwogt, J. M.; ten Bokkel Huinink, W. W.; Schellens, J. H. M.; Schot, M.; Mandjes, I. A. M.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H. Phase I clinical and pharmocokinetic study of PNU166945, a novel water soluble polymer-conjugated prodrug of paclitaxel. Anti-Cancer Drugs 2001, 12, 315-323.
28. Wrasidlo, W.; Niethammer, A.; Deger, S.; Sehouli, J.; Kulozik, A.; Geilen, W.; Henze, G.; Gaedicke, G.; Lode, H. N. Pilot study of hydrolytically activated paclitaxel prodrug therapy in patients with progressive malignancies. Curr. Ther. Res. 2002, 63, 247-262.
29. Singer, J. W.; Baker B.; De Vries P.; Kumar A.; Shaffer S.; Vawter E.; Bolton M.; Garzone P. Poly-(L)-glutamic acid-paclitaxel (CT-2103) [XYOTAX], a biodegradable polymeric drug conjugate: Characterization, preclinical pharmacology, and preliminary clinical data. Adv. Exp. Med. Biol. 2003, 519, 81-99.
30. Sparreboom, A.; Wolff, A. C.; Verweij, J.; Zabelina, Y.; van Zomeren, D. M.; McIntire, G. L.; Swindell, C. S.; Donehower, R. C.; Baker, S. D. Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: In vitro and clinical pharmacokinetic studies. Clin. Cancer Res. 2003, 9, 151-159.
31. Wolff, A. C.; Donehower, R. C.; Carducci, M. K.; Carducci, M. A.; Brahmer, J. R.; Zabelina, Y.; Bradley, M. O.; Anthony, F. H.; Swindell, C. S.; Witman, P. A.; Webb, N. L.; Baker, S. D. Phase I study of docosahexaenoic acid-paclitaxel: A taxane-fatty acid conjugate with a unique pharmacology and toxicity profile. Clin. Cancer Res. 2003, 9, 3589-3597.
32. Ettmayer, P.; Amidon, G. L.; Clement, B.; Testa, B. Lessons learned from marketed and investigational prodrugs. J. Med. Chem. 2004, 47, 2393-2404.
33. Kimura, T.; Ohtake, J.; Nakata, S.; Enomoto, H.; Moriwaki, H.; Akaji, K.; Kiso, Y. Synthesis of prodrug of HIV protease inhibitors. In Peptide Chemistry 1994, Ohno, M., Ed.; Protein Research Foundation: Osaka, 1995; Vol. 32, pp 157-160.
34. Kiso, Y.; Kimura, T.; Ohtake, J.; Nakata, S.; Enomoto, H.; Moriwaki, H.; Nakatani, M.; Akaji, K. "O→N Intramolecular acyl migration"-type prodrugs of tripeptide inhibitors of HIV protease. Peptides: Chemistry, Structure and Biology (Proceedings of the Fourteenth American Peptide Symposium); Mayflower Scientific: England, 1996; pp 157-159.
35. Yamaguchi, S.; Mitoguchi, T.; Nakata, S.; Kimura, T.; Akaji, K.; Nojima, S.; Takaku, H.; Mimoto, T.; Kiso, Y. Synthesis of HIV protease dipeptide inhibitors and prodrugs. In Peptide Chemistry 1996; Kitada, C., Ed.; Protein Research Foundation: Osaka, 1997; Vol. 34, pp 297-300.
36. Kiso, Y., Matsumoto, H.; Yamaguchi, S.; Kimura, T. Design of small peptidomimetic HIV-1 protease inhibitors and prodrug form. Lett. Pept. Sci. 1999, 6, 275-281.
37. Kiso, Y.; Yamaguchi, S.; Matsumoto, H.; Kimura, T.; Akaji, K. "O,N-Acyl migration"-type prodrug of dipeptide HIV protease inhibitors. Peptides: Frontiers of peptide science; Kluwer Academic Publishers: The Netherlands, 1999; pp 678-679.
38. Hamada, Y.; Ohtake, J.; Sohma, Y.; Kimura, T.; Hayashi, Y.; Kiso, Y. New water-soluble prodrugs of HIV protease inhibitors based on O→N intramolecular acyl migration. Bioorg. Med. Chem. 2002, 10, 4155-4167.
39. Hamada, Y.; Matsumoto, H.; Kimura, T.; Hayashi, Y.; Kiso, Y. Effect of the acyl groups on O→N acyl migration in the water-soluble prodrugs of HIV-1 protease inhibitor. Bioorg. Med. Chem. Lett. 2003, 13, 2727-2730.
40. Hamada, Y.; Matsumoto, H.; Yamaguchi, S.; Kimura, T.; Hayashi, Y.; Kiso, Y. Water-soluble prodrugs of dipeptide HIV protease inhibitors based on O→N intramolecular acyl migration: Design, synthesis and kinetic study. Bioorg. Med. Chem. 2004, 12, 159-170.
41. Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sohma, Y.; Kimura, T.; Kiso, Y. A Novel approach of water-soluble paclitaxel prodrug with no auxiliary and no byproduct: Design and synthesis of isotaxel. J. Med. Chem. 2003, 46, 3782-3784.
42. Skwarczynski, M.; Sohma, Y.; Kimura, M.; Hayashi, Y.; Kimura, T.; Kiso, Y. O→N Intramolecular acyl migration strategy in water-soluble prodrugs of taxoids. Bioorg. Med. Chem. Lett. 2003, 13, 4441-4444.
43. Sohma, Y.; Hayashi, Y.; Skwarczynski, M.; Hamada, Y.; Sasaki, M.; Kimura, T.; Kiso, Y. O-N Intramolecular acyl migration reaction in the development of prodrugs and the synthesis of difficult sequence-containing bioactive peptides. Biopolymers 2004, 76, 344-356.
44. Didier, E.; Fouque, E.; Taillepied, I.; Commerçon, A. 2-Mono-substituted-1,3-oxazolidines as improved protective groups of N-Boc-phenylisoserine in docetaxel preparation. Tetrahedron Lett. 1994, 35, 2349-2352.
45. Sisti, N. J.; Brinkman, H. R.; McChesney, J. D.; Chander, M. C.; Liang, X.; Zygmunt, J. Methods and useful intermediates for paclitaxel synthesis from C-7, C-10 di-Cbz 10-deacetylbaccatin III. US patent, 6,448,417, 2002.
46. Stewart J. M. Protection of the hydroxyl group in peptide synthesis. in The Peptides; Gross, E., Meienhofer, J., Eds.; Academic Press: New York, 1981; Vol. 3, pp 170-201.
47. Roh, E. J.; Kim, D.; Lee, C. O.; Choi, S. U.; Song, C. E. Structure-activity relationship study at the 3′-N-position of paclitaxel: Synthesis and biological evaluation of 3′-N-acyl-paclitaxel analogues. Bioorg. Med. Chem. 2002, 10, 3145-3151.
48. Roh, E. J.; Kim, D.; Choi, J. Y.; Lee, B.-S.; Lee, C. O.; Song, C. E. Synthesis, biological activity and receptor-based 3-D QSAR study of 3′-N-substituted-3′-N-debenzoylpaclitaxel analogues. Bioorg. Med. Chem. 2002, 10, 3135-3143.
49. Kobayashi, J. I.; Hosoyama, H. Wang, X.; Shigemori, H.; Koiso, Y.; Iwasaki, S.; Sasaki, T.; Naito, M.; Tsuruo, T. Effects of taxoids from Taxus cuspidata on microtubule depolymerization and vincristine accumulation in MDR cells. Bioorg. Med. Chem. Lett. 1997, 7, 393-398.
50. Zamir, L.; Caron, G.; Zheng, Y. F. US patent, 6,410,756, 1997; Chem. Abstr. 1998, 128, 321780.
51. Baloglu, E.; Hoch, J. M.; Chatterjee, S. K.; Ravindra, R.; Bane, S. Kingston, D. G. I. Synthesis and biological evaluation of C-3′NH/C-10 and C-2/C-10 modified paclitaxel analogues. Bioorg. Med. Chem. 2003, 11, 1557-1568.
52. Swindell, C. S.; Heerding, J. M.; Krauss, N. E.; Horwitz, S. B.; Ringel, I. Characterization of the Taxol structure-activity profile for the locus of the A-ring side chain. Bioorg. Med. Chem. Lett. 1994, 4, 1531-1536.
53. Stella, V. J. Prodrug as therapeutics. Exp. Opin. Ther. Patents 2004, 14, 277-280.
54. Brass, E. P. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol. Rev. 2002, 54, 589-598.
55. Luer, M. S. Fosphentoin. Neurol. Res. 1998, 20, 178-182.
56. Zhu, Q.; Guo, Z.; Huang, N.; Wang, M.; Chu, F. Comparative molecular field analysis of a series of paclitaxel analogues. J. Med. Chem. 1997, 40, 4319-4328.
57. Kingston, D. G. I. Recent advances in the chemistry of Taxol. J. Nat. Prod. 2000, 63, 726-734.
58. Kazmierski, W. M.; Bevans, P.; Furfine, E.; Spaltenstein, A.; Yang, H. Novel prodrug approach to Amprenavir-based HIV-1 protease inhibitors via O→N acyloxy migration of P1 moiety. Bioorg. Med. Chem. Lett. 2003, 13, 2523-2526.
59. Maring, C. J.; Grampovnik, D. J.; Yeung, C. M.; Klein, L. L.; Li, L.; Thomas, S. A.; Plattner, J. J. C-3′-N-acyl analogs of 9(R)-dihydrotaxol: Synthesis and structure-activity relationships. Bioorg. Med. Chem. Lett. 1994, 4, 1429-32.
60. Mastalerz, H.; Cook, D.; Fairchild, C. R.; Hansel, S.; Johnson, W.; Kadow, J. F.; Long, B. H.; Rose, W. C.; Tarrant, J.; Wu, M.-J.; Xue, M. Q. Zhang, G.; Zoeckler, M.; Vyas, D. M. The discovery of BMS-275183: An orally efficacious novel taxane. Bioorg. Med. Chem. 2003, 11, 4315-4323.